Charles River Laboratories International, Inc. Q4 2025 Earnings Call Summary

Management views New Approach Methodologies (NAMS) and AI as long-term enabling technologies rather than immediate disruptors to regulated safety assessment environments.Manufacturing segment growth was hindered by the loss of a major commercial cell therapy client, though Microbial Solutions maintained strong performance across all testing platforms.Discovery Services volume declines impacted DSA revenue, while pricing and mix remained stable across the broader segment.The acquisition of KF Cambodia is a s ...